Understanding how Epstein Barr virus causes lymphoma in people with HIV/AIDS
EBV reactivation causes widespread host de novo promoter transcription and transcriptional interference
This research explores how the Epstein Barr virus, common in people with HIV/AIDS, switches from a quiet state to an active one, which can lead to lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11114001 on NIH RePORTER |
What this research studies
Most people carry the Epstein Barr virus (EBV) without issues, but in individuals with HIV/AIDS, it can become active and cause a type of cancer called lymphoma. This project aims to uncover the specific ways EBV reactivates and takes over human cells, particularly how it interferes with the cell's normal processes. By understanding these detailed steps, we hope to learn why EBV-related cancers are more common in the HIV/AIDS community. This knowledge could help us find new ways to prevent or treat these cancers.
Who could benefit from this research
Good fit: This foundational research focuses on understanding the disease mechanism and does not directly involve patient participation, but it is highly relevant for individuals with HIV/AIDS who are at risk for EBV-associated lymphomas.
Not a fit: Patients without HIV/AIDS or those not at risk for EBV-associated lymphomas may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating EBV-associated lymphomas in people living with HIV/AIDS.
How similar studies have performed: Other studies have established links between EBV lytic replication and associated cancers, and this work builds upon existing knowledge of how viruses interact with host cells.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Flemington, Erik K — Tulane University of Louisiana
- Study coordinator: Flemington, Erik K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.